BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

119 related articles for article (PubMed ID: 21262370)

  • 1. Intracellular delivery of serum-derived hepatitis C virus.
    Fukuhara T; Tani H; Shiokawa M; Goto Y; Abe T; Taketomi A; Shirabe K; Maehara Y; Matsuura Y
    Microbes Infect; 2011 Apr; 13(4):405-12. PubMed ID: 21262370
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Serum-derived hepatitis C virus infection of primary human hepatocytes is tetraspanin CD81 dependent.
    Molina S; Castet V; Pichard-Garcia L; Wychowski C; Meurs E; Pascussi JM; Sureau C; Fabre JM; Sacunha A; Larrey D; Dubuisson J; Coste J; McKeating J; Maurel P; Fournier-Wirth C
    J Virol; 2008 Jan; 82(1):569-74. PubMed ID: 17942559
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Replication-competent recombinant vesicular stomatitis virus encoding hepatitis C virus envelope proteins.
    Tani H; Komoda Y; Matsuo E; Suzuki K; Hamamoto I; Yamashita T; Moriishi K; Fujiyama K; Kanto T; Hayashi N; Owsianka A; Patel AH; Whitt MA; Matsuura Y
    J Virol; 2007 Aug; 81(16):8601-12. PubMed ID: 17553880
    [TBL] [Abstract][Full Text] [Related]  

  • 4. High density lipoprotein inhibits hepatitis C virus-neutralizing antibodies by stimulating cell entry via activation of the scavenger receptor BI.
    Dreux M; Pietschmann T; Granier C; Voisset C; Ricard-Blum S; Mangeot PE; Keck Z; Foung S; Vu-Dac N; Dubuisson J; Bartenschlager R; Lavillette D; Cosset FL
    J Biol Chem; 2006 Jul; 281(27):18285-95. PubMed ID: 16675450
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A robust model of natural hepatitis C infection using hepatocyte-like cells derived from human induced pluripotent stem cells as a long-term host.
    Sa-Ngiamsuntorn K; Wongkajornsilp A; Phanthong P; Borwornpinyo S; Kitiyanant N; Chantratita W; Hongeng S
    Virol J; 2016 Apr; 13():59. PubMed ID: 27044429
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Identification of a novel epitope in the C terminus of hepatitis C virus-E2 protein that induces potent and cross-reactive neutralizing antibodies.
    Das S; Mullick R; Kumar A; Tandon H; Bose M; Gouthamchandra K; Chandra M; Ravishankar B; Khaja MN; Srinivasan N; Das S; Melkote Subbarao S; Karande AA
    J Gen Virol; 2017 May; 98(5):962-976. PubMed ID: 28221101
    [TBL] [Abstract][Full Text] [Related]  

  • 7. CD81 Receptor Regions outside the Large Extracellular Loop Determine Hepatitis C Virus Entry into Hepatoma Cells.
    Banse P; Moeller R; Bruening J; Lasswitz L; Kahl S; Khan AG; Marcotrigiano J; Pietschmann T; Gerold G
    Viruses; 2018 Apr; 10(4):. PubMed ID: 29677132
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Low cross-neutralization of hepatitis C correlates with liver disease in immunocompromized patients.
    Maurin G; Halgand B; Bruscella P; Fresquet J; Duclos-Vallée JC; Roque-Afonso AM; Cosset FL; Samuel D; Lavillette D; Féray C
    AIDS; 2015 Jun; 29(9):1025-33. PubMed ID: 26125137
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Mouse monoclonal antibody towards e1 specific epitope blocks viral entry and intracellular viral replication in vitro.
    Tabll AA; Moustafa RI; El Abd YS; Bader El Din NG; El-Shenawy R; Yousef H; Hussein M; Dawood RM; Omran MH; El-Awady MK
    J Immunoassay Immunochem; 2014; 35(1):60-73. PubMed ID: 24063617
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The association of CD81 with tetraspanin-enriched microdomains is not essential for Hepatitis C virus entry.
    Rocha-Perugini V; Lavie M; Delgrange D; Canton J; Pillez A; Potel J; Lecoeur C; Rubinstein E; Dubuisson J; Wychowski C; Cocquerel L
    BMC Microbiol; 2009 May; 9():111. PubMed ID: 19476617
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Combination of neutralizing monoclonal antibodies against Hepatitis C virus E2 protein effectively blocks virus infection.
    Bose M; Mullick R; Das S; Das S; Karande AA
    Virus Res; 2016 Sep; 224():46-57. PubMed ID: 27574733
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Hepatitis C virus entry into hepatocytes: molecular mechanisms and targets for antiviral therapies.
    Zeisel MB; Fofana I; Fafi-Kremer S; Baumert TF
    J Hepatol; 2011 Mar; 54(3):566-76. PubMed ID: 21146244
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Interaction of hepatitis C virus-like particles and cells: a model system for studying viral binding and entry.
    Triyatni M; Saunier B; Maruvada P; Davis AR; Ulianich L; Heller T; Patel A; Kohn LD; Liang TJ
    J Virol; 2002 Sep; 76(18):9335-44. PubMed ID: 12186916
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A Diverse Panel of Hepatitis C Virus Glycoproteins for Use in Vaccine Research Reveals Extremes of Monoclonal Antibody Neutralization Resistance.
    Urbanowicz RA; McClure CP; Brown RJ; Tsoleridis T; Persson MA; Krey T; Irving WL; Ball JK; Tarr AW
    J Virol; 2015 Dec; 90(7):3288-301. PubMed ID: 26699643
    [TBL] [Abstract][Full Text] [Related]  

  • 15. An Optimized Hepatitis C Virus E2 Glycoprotein Core Adopts a Functional Homodimer That Efficiently Blocks Virus Entry.
    McCaffrey K; Boo I; Owczarek CM; Hardy MP; Perugini MA; Fabri L; Scotney P; Poumbourios P; Drummer HE
    J Virol; 2017 Mar; 91(5):. PubMed ID: 28031364
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Inhibition of hepatitis C virus-like particle binding to target cells by antiviral antibodies in acute and chronic hepatitis C.
    Steinmann D; Barth H; Gissler B; Schürmann P; Adah MI; Gerlach JT; Pape GR; Depla E; Jacobs D; Maertens G; Patel AH; Inchauspé G; Liang TJ; Blum HE; Baumert TF
    J Virol; 2004 Sep; 78(17):9030-40. PubMed ID: 15308699
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Identification of Piperazinylbenzenesulfonamides as New Inhibitors of Claudin-1 Trafficking and Hepatitis C Virus Entry.
    Riva L; Song OR; Prentoe J; Helle F; L'homme L; Gattolliat CH; Vandeputte A; Fénéant L; Belouzard S; Baumert TF; Asselah T; Bukh J; Brodin P; Cocquerel L; Rouillé Y; Dubuisson J
    J Virol; 2018 May; 92(10):. PubMed ID: 29491159
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Hepatitis C Virus Infection of Cultured Cells and Primary Human Hepatocytes.
    Lowey B; Li Q
    Curr Protoc Cell Biol; 2018 Sep; 80(1):e54. PubMed ID: 30058773
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Syntenin regulates hepatitis C virus sensitivity to neutralizing antibody by promoting E2 secretion through exosomes.
    Deng L; Jiang W; Wang X; Merz A; Hiet MS; Chen Y; Pan X; Jiu Y; Yang Y; Yu B; He Y; Tu Z; Niu J; Bartenschlager R; Long G
    J Hepatol; 2019 Jul; 71(1):52-61. PubMed ID: 30880226
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Saikosaponin b2 is a naturally occurring terpenoid that efficiently inhibits hepatitis C virus entry.
    Lin LT; Chung CY; Hsu WC; Chang SP; Hung TC; Shields J; Russell RS; Lin CC; Li CF; Yen MH; Tyrrell DL; Lin CC; Richardson CD
    J Hepatol; 2015 Mar; 62(3):541-8. PubMed ID: 25450204
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.